An interventional study of VIOME Precision Nutrition Program and VIOME-designed condition-based supplements in Gastrointestinal Health, sponsored by Viome. Recruiting at 1 site in United States. Open to participants aged 25 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-01-29.
Sponsored by Viome · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 292 studies in Nausea with a site in United States — 31 open to participants now, 34 under way, 8 of them phase 3. Nausea · United States.
Among the 292 studies in Nausea with a site in United States, this one is the 77th largest by planned enrollment of the 262 interventional ones that give a count, is one of 12 that started in 2022, is one of 103 with no phase, reaches primary completion later than 7 of the 33 other live ones, and was the 261st registered.
646 studies on the registry are indexed under Nausea; 87 are open to participants now.
Browse Nausea studies →31 of the 292 studies in Nausea with a site in United States are open now. Recruiting first, the newest first:
Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Sites in United States
Ages 18–65 · Healthy volunteers
University of Southern California · Sites in United States
Ages 18–49 · Women only · Healthy volunteers
Vanda Pharmaceuticals · Sites in United States
Ages 18–65 · Healthy volunteers
University of Minnesota · Sites in United States
Ages 18+ · Women only
Eli Lilly and Company · Sites in United States, Australia, China and 7 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 53 Nausea studies recruiting now, 23 (43%) set no upper age limit and 19 (36%) stop at 75 or younger; 10 take children under 18; 13 take healthy volunteers.
This study: 25 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
292 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 29 · Phase 2 62 · Phase 3 49 · Phase 4 38
First in 1999; this study’s year is marked. 12 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 96 across 546 interventional studies indexed under Nausea.
Median enrollment 86 across the 262 interventional studies, 106 across the 25 observational. Of the 227 that completed or were terminated, 118 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
77 of 292 have an industry lead sponsor. The 10 most frequent:
Viome is the lead sponsor of 25 studies on the registry; 13 are open to participants now.
Viome has 1 study filed under Nausea — fewer than ten, so there is no comparison to draw.
15 of the studies in Nausea with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07446439Phase 3Vanda PharmaceuticalsA Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use | 2026-12-01 |
| NCT06382012Phase 3Montefiore Medical CenterAntiemetic Fosaprepitant To Remedy Nausea and Vomiting | 2027-03 |
| NCT05418244Phase 3State University of New York at BuffaloInhaled Isopropyl Alcohol for Treatment of Nausea | 2027-06-30 |
| NCT06588413Phase 3Augusta UniversityOlanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan | 2027-10 |
| NCT01696734Phase 3M.D. Anderson Cancer CenterDomperidone in Treating Patients With Gastrointestinal Disorders | 2027-10-31 |
Add all 15 to your calendar (.ics) → With an account.
Among the 292 studies in Nausea with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
US residents who have gastrointestinal issues sign the informed consent form and are screened and enrolled for this study. Participants who are enrolled complete a survey upon enrollment and are randomized into one of three arms. This study is direct to participant and will NOT utilize clinical sites.
Participants who meet the eligibility criteria are randomized into any of the three arms including: the control arm, VIOME's condition-based supplements (VCS) arm or the VIOME Precision Nutrition Program (VPNP) arm.
Placebo, Viome-designed condition-based supplements and Viome's Precision Nutrition Program include supplements, may include dietary recommendations towards improving the symptoms associated with gastrointestinal wellness. The trial will last approximately 4 months for each participant.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria
FODMAP KETO PALEO
Appendectomy and benign polypectomy
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who have gastrointestinal issues are randomized into this arm. They may be provided with any combination of nutritional recommendations and supplements. Placebo capsules will contain inert and inactive materials. Participants may need to use a mobile app in order to participate in the trial.
Participants who have gastrointestinal issues are randomized into this arm. They may be provided with any combination of nutritional recommendations and supplements. Participants may need to use a mobile app in order to participate in the trial.
Combination Product: VIOME Precision Nutrition Program
Participants who have gastrointestinal issues are randomized into this arm. They may be provided with any combination of nutritional recommendations and supplements. Participants may need to use a mobile app in order to participate in the trial.
Dietary Supplement: VIOME-designed condition-based supplements
Precision supplement based on the participants microbiome sample results. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.
Also known as: VPNP
Pre-formulated supplements based on overall health conditions. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.
Also known as: VCS
Efficacy of VIOME's designed condition based supplements (VCS)
Number of participants that show an improvement in GI health compared to baseline survey assessment.
Time frame: ~4 months
Efficacy of VIOME Precision Nutrition Program (VPNP)
Number of participants that show an improvement in GI health compared to baseline survey assessment.
Time frame: ~4months
Started Nov 2022 (actual). Primary completion is estimated for Dec 2026, 49 months after the start.
Of 126 interventional studies with no phase under Nausea, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's planned 49 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.